Tyme Technologies Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
- Financing Rounds
-
7
- Investments
-
1
Tyme Technologies General Information
Description
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.
Contact Information
Website
www.tymeinc.comCorporate Office
- 1 Pluckemin Way
- Suite 103
- Bedminster, NJ 07921
- United States
Corporate Office
- 1 Pluckemin Way
- Suite 103
- Bedminster, NJ 07921
- United States
Tyme Technologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tyme Technologies Comparisons
Industry
Financing
Details
Tyme Technologies Competitors (2)
One of Tyme Technologies’s 2 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
Tyme Technologies Patents
Tyme Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4175938-A1 | Crystalline forms of metyrosine | Inactive | 01-Jul-2020 | ||
| US-20220002227-A1 | Crystalline forms of metyrosine | Inactive | 01-Jul-2020 | ||
| WO-2022006366-A1 | Crystalline forms of metyrosine | Inactive | 01-Jul-2020 | ||
| EP-3909587-A1 | Methods of treating sars-cov-2 infections | Inactive | 14-May-2020 | ||
| US-10905698-B1 | Methods of treating sars-cov-2 infections | Inactive | 14-May-2020 | A61K31/575 |
Tyme Technologies Signals
Tyme Technologies Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tyme Technologies Acquisitions (1)
Tyme Technologies’s most recent deal was a Merger/Acquisition with Tyme. The deal was made on 19-Mar-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tyme | 19-Mar-2015 | Merger/Acquisition | Beverages |
Tyme Technologies FAQs
-
When was Tyme Technologies founded?
Tyme Technologies was founded in 2011.
-
Where is Tyme Technologies headquartered?
Tyme Technologies is headquartered in Bedminster, NJ.
-
What is the size of Tyme Technologies?
Tyme Technologies has 13 total employees.
-
What industry is Tyme Technologies in?
Tyme Technologies’s primary industry is Biotechnology.
-
Is Tyme Technologies a private or public company?
Tyme Technologies is a Private company.
-
What is the current valuation of Tyme Technologies?
The current valuation of Tyme Technologies is .
-
What is Tyme Technologies’s current revenue?
The current revenue for Tyme Technologies is .
-
How much funding has Tyme Technologies raised over time?
Tyme Technologies has raised $35M.
-
Who are Tyme Technologies’s investors?
Eagle Pharmaceuticals, Global Emerging Markets, LDA Capital, and Tyme have invested in Tyme Technologies.
-
Who are Tyme Technologies’s competitors?
Inovio Pharmaceuticals and Agenus are competitors of Tyme Technologies.
-
When was Tyme Technologies acquired?
Tyme Technologies was acquired on 16-Sep-2022.
-
Who acquired Tyme Technologies?
Tyme Technologies was acquired by Syros Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process